WATCHLONGEVITY

Saturday, June 20, 2026

April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Importance
62
Trust
80
Urgency
30
SAFETY · PRIMARY SOURCE

April - June 2022 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

The FDA found that GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro may cause intestinal blockages. The agency updated drug labels between late 2022 and mid-2023 to warn patients about this risk.

Analysis

FDA added intestinal blockage warnings to all GLP-1 drug labels. Patients on Ozempic, Wegovy, and Mounjaro need to know this risk is now official.

  • FDA updated GLP-1 drug labels between November 2022 and September 2023 to include ileus risk
  • Drugs affected include Mounjaro (tirzepatide), Ozempic, Wegovy, Rybelsus (all semaglutide), and others
  • The ileus warning was added to the 'Adverse Reactions' section of affected drug labeling
$NVO$LLY
semaglutidetirzepatideliraglutidedulaglutide
FDA Drug Approvals & Databases8d
Read
October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
DEVELOPING
Importance
72
Trust
70
Urgency
65
SAFETY · PRIMARY SOURCE

October - December 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

Analysis

FDA is reviewing a possible link between GLP-1 drugs and blindness (NAION). Ozempic, Wegovy, Mounjaro, and Zepbound are all on the list.

  • FDA flagged GLP-1 receptor agonists for non-arteritic anterior ischemic optic neuropathy (NAION)
  • Drugs named include Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound
  • FDA is evaluating the need for regulatory action as of March 6, 2025
$NVO$LLY
lixisenatideexenatidetirzepatidesemaglutide
FDA Drug Approvals & Databases8d
Read
January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
Importance
62
Trust
70
Urgency
30
SAFETY · PRIMARY SOURCE

January - March 2024 | New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

The FDA listed GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound as having a possible safety signal for a nerve problem called dysaesthesia (abnormal skin sensations). The agency is still studying whether the drugs caused these reports and whether label changes are needed.

Analysis

FDA flagged a nerve sensation problem linked to Ozempic, Wegovy, Mounjaro, and Zepbound. No label changes yet, but the agency is still deciding what to do.

  • FDA identified dysaesthesia as a potential safety signal for the full GLP-1 receptor agonist drug class
  • Named drugs include Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta
  • As of June 21, 2024, FDA is evaluating the need for regulatory action — no label changes made yet
$NVO$LLY
semaglutidetirzepatideliraglutideexenatide
FDA Drug Approvals & Databases8d
Read